QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Tarlatamab, DLL3×CD3 T-Cell Engagement, ES-SCLC and Product Pharmacovigilance

Test your understanding of the concepts covered by Tarlatamab: DLL3×CD3 T-Cell Engagement, Small-Cell Lung Cancer and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which scenario most strongly suggests the need to review restart or re-escalation instructions?

A patient receives each scheduled dose on time without toxicity A patient resumes treatment after a prolonged interruption without confirmation that the required step-up and monitoring rules were applied A patient has a stable blood count before Cycle 1 Day 1 A patient receives a caregiver reminder before an early-cycle infusion

Question 2 of 10 Which case narrative would be most complete for a serious CRS report?

CRS occurred after treatment; the patient recovered Fever occurred in a patient with cancer and was treated in hospital Cycle/day and dose, onset from infusion start, vital-sign and oxygen findings, interventions, infectious evaluation, outcome and subsequent dosing plan The patient received an immune therapy and later felt unwell

Question 3 of 10 Which clinical context is especially important when distinguishing hypoxia from CRS in a patient with ES-SCLC?

The possibility of pneumonia, pulmonary embolism, baseline lung disease or tumour-related respiratory compromise The patient's preferred chemotherapy regimen from a previous line The absence of a CD3-positive lymphocyte count in the case report The fact that all hypoxia after infusion is necessarily allergic

Question 4 of 10 A patient develops fever, hypotension and hypoxia 12 hours after the first 10 mg dose. Cultures are negative, imaging shows no new infection, and the patient improves after corticosteroid and tocilizumab treatment. What is the most appropriate interpretation?

The case is compatible with CRS, while the negative infectious evaluation remains relevant supporting information The case must be classified as infection because fever after anticancer treatment is never CRS The response to tocilizumab proves that infection was absent and no differential diagnosis is needed The case should be classified only as an infusion reaction because all immune toxicities are interchangeable

Question 5 of 10 For a tarlatamab-associated CRS case, how should onset timing be recorded for pharmacovigilance purposes?

Only as the calendar date on which the patient first contacted the hospital From the end of the infusion, because the infusion itself is not part of exposure From the start of the infusion, with the elapsed time documented precisely Only by treatment cycle, without recording hours after administration

Question 6 of 10 What is the principal pharmacovigilance value of documenting caregiver and healthcare-setting instructions after early doses?

They establish tumour response independently of treatment exposure They help determine whether delayed toxicity could be recognised and managed promptly and whether risk-minimisation measures were implemented They replace the need for clinical assessment when neurologic symptoms occur They demonstrate that any subsequent adverse event is unrelated to treatment

Question 7 of 10 Which set of information would provide the strongest pharmacovigilance assessment of suspected ICANS?

Only the patient's tumour response and the date of the next planned dose Baseline CNS disease, neurologic examination, ICE-score trajectory, imaging or EEG, metabolic testing and treatment response Only the presence or absence of fever The number of DLL3-positive cells measured in the original tumour specimen

Question 8 of 10 Which statement about ICANS is most accurate?

ICANS is defined by a single diagnostic laboratory test ICANS can occur only when CRS is present at the same time ICANS is a clinical neurologic syndrome that requires assessment alongside alternative causes ICANS is synonymous with progressive brain metastases in patients with SCLC

Question 9 of 10 Why is monitoring more intensive after the earliest tarlatamab doses than after later tolerated doses?

Tarlatamab accumulates permanently after every dose, so later doses are intrinsically more toxic The strongest acute cytokine responses and most frequent CRS events occur during initial T-cell engagement Patients lose all risk of infection after the first treatment cycle Later doses do not activate T cells and therefore require monitoring only for infusion-site reactions

Question 10 of 10 Why can infection and CRS not be treated as mutually exclusive diagnoses in a tarlatamab case?

Tarlatamab prevents all infections but causes sterile fever in every treated patient The syndromes share clinical features, and infection may coexist with immune-mediated inflammation Negative cultures are always required before CRS can be diagnosed Antibiotic treatment eliminates the possibility of CRS

QPPV.com

Knowledge Assessment: Tarlatamab, DLL3×CD3 T-Cell Engagement, ES-SCLC and Product Pharmacovigilance

Cookie Settings